asia pacific pharmaceutical continuous manufacturing Market

Asia Pacific pharmaceutical continuous manufacturing market is anticipated to reach US$ 604.91 million by 2027 from US$ 274.10 million in 2019. The market is projected to grow at a CAGR of 10.5% from 2019 to 2027.

The pharmaceutical continuous manufacturing market is growing primarily due to the advantages offered by continuous manufacturing process. Restraining factors, such as advantages offered by continuous manufacturing process is likely to damage the growth of the market in the coming years. On the other hand, low R&D funding by government in developing economies is expected to have a positive impact on the growth of the Asia Pacific pharmaceutical continuous manufacturing market in the coming years.

Continuous manufacturing in the pharmaceutical industry is a result of advancements in technology with respect to the production techniques. The batch manufacturing method was traditionally followed in the pharmaceutical industry. However, the development in technology has accelerated mass production with improved quality, and it has addressed the several primary causes such as the recall of drugs and recalls. The pharmaceutical industry has recently begun to acknowledge the continuous manufacturing process as an option to improve and sustain manufacturing operations. More than 300 pharmaceutical continuous manufacturing companies are established in the regions such as Missouri, Columbia, Kansas, and Manhattan.

Batch manufacturing has been the most common and traditional mode of manufacturing in the pharmaceutical industry for more than a century. However, with the rising demand for biologics and increasing trend of contract manufacturing, the flexible manufacturing alternatives such as continuous manufacturing processes are being embraced and gaining importance in the recent years. The FDA is passing quick approvals to companies transitioning from batch production to continuous manufacturing procedures. Continuous pharmaceutical manufacturing involves end to end process from a drug taken from its base ingredients to final product with no need of halt or stop during the production. According to the Food and Drug Administration (FDA), the pharmaceutical manufacturing industry wastes up to $50 billion every year on inefficient processes. Continuous manufacturing serves to be a potential solution for the same problem. Additionally, there are various other advantages offered by the continuous manufacturing process, such as time-efficiency, reduced energy needs, increased productivity, and reduction in overall wastage amounts. Further, the risk of human error is also reduced in the continuous manufacturing process due to the involvement of minimum number of people in the manufacturing process. Thus, the advantages offered by continuous manufacturing over batch manufacturing procedure are expected to drive the growth of the market over the coming years.

Considering the geographic and economical operations between Asian countries and China, the countries are expected to witness the challenge of COVID-19. The COVID-19 outbreak has severely affected all the businesses along with the supply chain disruptions and problems posed by the shortage of healthcare infrastructure in low-income countries. To reduce the spread of COVID-19, restrictive measures have been taken in South Korea, Malaysia, Singapore, the Philippines, and India. Domestic startups backed by international funding have already started witnessing back out from investors putting the development of the products in jeopardy.

In terms of product, the integrated systems segment accounted for the largest share of the Asia Pacific pharmaceutical continuous manufacturing market in 2019 and is estimated to mark the highest CAGR in the market during the forecast period, owing to the factors such as their easy availability and accessibility as well as higher adoption of these systems compared to the semi-continuous systems and the controls. Also, the convenience of use of upright freezers has led to its dominance during 2019 and is expected to witness similar trend over the coming years.

Centers For Disease Control And Prevention (CDC), Defense Research and Development Organization (DRDO), Rashtriya Swasthya Bima Yojna (RSBY), World Health Organization (WHO) are among the significant primary and secondary sources for pharmaceutical continuous manufacturing included in the report.